Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medicus Pharma Ltd ( (MDCX) ) just unveiled an update.
Medicus Pharma has received U.S. FDA “study may proceed” clearance to initiate a Phase 2b dose-optimization trial of its investigational drug Teverelix in men with advanced prostate cancer who are candidates for androgen deprivation therapy. The open-label study will enroll 40 patients and is designed to confirm rapid and durable medical castration, evaluate follicle-stimulating hormone suppression, and assess cardiovascular safety over roughly 22 weeks of treatment.
Teverelix is a long-acting injectable GnRH antagonist that avoids the testosterone surge associated with GnRH agonists and may offer cardiovascular advantages for patients with elevated cardiovascular risk. With regulatory alignment on a development path and a cardiovascular-risk–focused labeling strategy, Medicus aims to position Teverelix as a best-in-class therapy and potential new backbone treatment in a U.S. advanced prostate cancer market estimated at more than $4 billion annually.
The most recent analyst rating on (MDCX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd., listed on Nasdaq, is a precision-guided biotech and life sciences company developing novel and potentially disruptive therapeutic assets. The company is currently focused on advancing Teverelix, a next-generation long-acting GnRH antagonist targeting advanced prostate cancer patients with high cardiovascular risk and acute urinary retention relapse prevention, addressing an estimated multibillion-dollar market.
Average Trading Volume: 323,027
Technical Sentiment Signal: Sell
Current Market Cap: $28.36M
For an in-depth examination of MDCX stock, go to TipRanks’ Overview page.